A Phase II Study of MGCD0103 (MG-0103) in Patients With Acute Myelogenous Leukemia/High Risk MDS Who Are Elderly and Have Previously Untreated Disease or Who Are Adult and Have Relapsed/Refractory Disease.

Trial Profile

A Phase II Study of MGCD0103 (MG-0103) in Patients With Acute Myelogenous Leukemia/High Risk MDS Who Are Elderly and Have Previously Untreated Disease or Who Are Adult and Have Relapsed/Refractory Disease.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2015

At a glance

  • Drugs Mocetinostat (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MethylGene; Mirati Therapeutics
  • Most Recent Events

    • 12 May 2009 Additional lead trial investigator Martell R identified as reported by ClinicalTrials.gov.
    • 16 Dec 2008 Status changed from suspended to discontinued, based on information provided by clinicaltrials.gov. The Clinical Development Program for MG 0103 is being re-evaluated.
    • 23 Jul 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top